This trial is testing whether a new treatment for leukemia, which uses cells from another person, followed by a different drug, can help reduce relapse rates and improve survival.
1 Primary · 12 Secondary · Reporting Duration: Days +19, +91, +135 and +180 post-HCT
Experimental Treatment
25 Total Participants · 2 Treatment Groups
Primary Treatment: Blinatumomab · No Placebo Group · Phase 2
Age < 65 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: